Molecular/genetic therapies in ovarian cancer: future opportunities and challenges

• Published in: Clinical obstetrics and gynecology Vol. 55; no. 1; p. 156
• Main Authors: Ziebarth, Angela J, Landen, Jr, Charles N, Alvarez, Ronald D
• Format: Journal Article
• Language: English
• Published: United States 01.03.2012
• Subjects: Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents - therapeutic use; Bevacizumab; CA-125 Antigen; Clinical Trials as Topic; Enzyme Inhibitors - therapeutic use; Female; Folate Receptor 1 - antagonists & inhibitors; Genes, BRCA1; Genes, BRCA2; Genetic Therapy; Histone Deacetylase Inhibitors - therapeutic use; Humans; Insulin-Like Growth Factor Binding Protein 1 - antagonists & inhibitors; Interleukin-12 - therapeutic use; Mutation; Oncogene Protein v-akt - antagonists & inhibitors; Ovarian Neoplasms - blood supply; Ovarian Neoplasms - drug therapy; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors - therapeutic use; Receptors, TNF-Related Apoptosis-Inducing Ligand - antagonists & inhibitors; Sirolimus - analogs & derivatives; Sirolimus - therapeutic use; Taxoids - therapeutic use; Vascular Endothelial Growth Factor A - antagonists & inhibitors

Ovarian cancer is the most lethal gynecologic cancer. Traditional therapies have included surgical management and cytotoxic chemotherapy; however, treatment paradigms continue to shift from empiric cytotoxic chemotherapy to more individualized treatment. Recent research efforts have focused on deter...